Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 187

The DOI matches its Crossref record.

Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer

Open access
Liedtke, Cornelia, Hatzis, Christos, Symmans, William Fraser, Desmedt, Christine, Haibe-Kains, Benjamin, Valero, Vicente, Kuerer, Henry, Hortobagyi, Gabriel N., Piccart-Gebhart, Martine, Sotiriou, Christos, Pusztai, Lajos·2009·Journal of Clinical Oncology

Abstract

Purpose: The genomic grade index (GGI) is a 97-gene measure of histological tumor grade. High GGI is associated with decreased relapse-free survival in patients receiving either endocrine or no systemic adjuvant therapy. Herein we examined whether GGI predicts pathologic response to neoadjuvant chemotherapy in patients with HER-2–normal breast cancer. Methods: Gene expression data (gene chips) was generated from fine-needle aspiration biopsies (n = 229) prospectively collected before neoadjuvant paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy. Pathologic response was quantified using the residual cancer burden (RCB) method. The association between the GGI and pathologic response was assessed in univariate and multivariate analyses. The performance of a response predictor combining clinical variables and GGI was evaluated under cross-validation. Results: Eighty-five percent of grade 1 tumors had low GGI, 89% of grade 3 tumors had high GGI, and 63% of grade 2 tumors had low GGI. Among both estrogen receptor (ER)-positive and -negative cancers, high GGI score was associated with pathologic complete response (RCB-0) or minimal residual disease (RCB-1). A multivariate model combining GGI and clinical parameters had an overall accuracy of 71%, compared with 58% for the GGI alone, for prediction of pathologic response. However, high GGI score was also associated with significantly worse distant relapse-free survival in patients with ER-positive cancer (P = .005), and was not associated with survival in patients with ER-negative cancer. Conclusion: High GGI is associated with increased sensitivity to neoadjuvant paclitaxel plus fluorouracil, adriamycin, and cyclophosphamide chemotherapy in both ER-negative and ER-positive patients, but it remains a predictor of worse survival in ER-positive patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.18.5934

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 187

Metadata

Authors
Liedtke, C., Hatzis, C., Symmans, W. F., Desmedt, C., Haibe-Kains, B., Valero, V., Kuerer, H., Hortobagyi, G. N., Piccart-Gebhart, M., Sotiriou, C., & Pusztai, L.
Venue
Journal of Clinical Oncology
Published
2009-07-01
Volume
27
Issue
19
Pages
3185-3191
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2120236927
Cited by
187
References
0
FWCI
7.38
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2008.18.5934
The paper
Liedtke, C., Hatzis, C., Symmans, W. F., Desmedt, C., Haibe-Kains, B., Valero, V., Kuerer, H., Hortobagyi, G. N., Piccart-Gebhart, M., Sotiriou, C., & Pusztai, L. (2009). Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.18.5934

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.